Investment Thesis
Zimmer Biomet exhibits strong free cash flow generation (323M, 15.5% FCF margin) and healthy operating margins (17.9%), but recent major acquisition has suppressed net profitability and returns on capital. The critically low ROE (1.9%) and ROA (1.0%) indicate poor efficiency in deploying shareholder capital, while tight interest coverage (1.7x) leaves limited room for earnings deterioration.
Strengths
- Exceptional free cash flow generation ($323.1M with 15.5% FCF margin) demonstrates earnings quality
- Healthy gross margin (61.6%) and operating margin (17.9%) in core business operations
- Conservative leverage with 0.50x debt-to-equity ratio and manageable debt service
Risks
- Severely depressed returns on equity (1.9%) and assets (1.0%) indicate massive capital inefficiency post-acquisition
- Tight interest coverage (1.7x) provides minimal cushion; any earnings decline threatens debt covenants
- Net income flat despite 2911% revenue growth signals substantial integration costs and margin compression that may persist
Key Metrics to Watch
- Return on equity recovery trajectory as acquisition integrates
- Interest coverage ratio sustainability with current debt load
- Operating margin normalization and SG&A leverage improvement
- Free cash flow conversion and organic growth separation from acquisition effects
Financial Metrics
Revenue
2.1B
Net Income
238.1M
EPS (Diluted)
$1.22
Free Cash Flow
323.1M
Total Assets
22.7B
Cash
424.2M
Profitability Ratios
Gross Margin
61.6%
Operating Margin
17.9%
Net Margin
11.4%
ROE
1.9%
ROA
1.0%
FCF Margin
15.5%
Balance Sheet & Liquidity
Current Ratio
1.73x
Quick Ratio
0.95x
Debt/Equity
0.50x
Debt/Assets
44.2%
Interest Coverage
1.67x
Long-term Debt
6.3B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T14:12:30.460070 |
Data as of: 2026-03-31 |
Powered by Claude AI